Read about the latest advances from the Lady Davis Institute for Medical Research (LDI) and its researchers, including new findings, grant awards, innovations, and collaborations.
Lady Davis Institute for Medical Research investigators awarded more than $12.9M from CIHR
Twelve research teams from the LDI were awarded $12,903,057 in combined funding through the Canadian Institutes of Health Research (CIHR) Fall 2025 Project Grant and Team Grants: Bringing Biology to Cancer Prevention competitions.
Cutting-edge study highlights the role of a new blood test that may help decide who needs chemotherapy in patients with aggressive breast cancer
The research provides new insights into the prognostic value of ctDNA and its ability to guide personalized treatment strategies for patients with triple-negative breast cancer.
New study links GLP-1 receptor agonists to increased risk of gastroesophageal reflux disease (GERD) in type 2 diabetes patients
The study shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which include Ozempic®, Rybelsus® and other widely- prescribed drugs for type 2 diabetes and obesity management, may increase the risk of developing gastroesophageal reflux disease (GERD) and its complications compared to sodium–glucose cotransporter-2 (SGLT-2) inhibitors (such as Brenzavvy™, Invokana®, etc.).
